| Autor: |
Wang-Da Liu, Meng-Shuan Lin, Hsin-Yun Sun, Ming-Chieh Shih, Yu-Chung Chuang, Yu-Shan Huang, Kuan-Yin Lin, Guei-Chi Li, Pei-Ying Wu, Ling-Ya Chen, Wen-Chun Liu, Yi-Ching Su, Pu-Chi He, Yi-Ting Chen, Chia-Yi Lin, Yu-Chen Cheng, Yi Yao, Yi-Chen Yeh, Chia-Chi Liu, Mei-Yan Pan, Yu-Zhen Luo, Hsi-Yen Chang, Jann-Tay Wang, Wang-Huei Sheng, Szu-Min Hsieh, Sui-Yuan Chang, Chien-Ching Hung |
| Jazyk: |
angličtina |
| Rok vydání: |
2024 |
| Předmět: |
|
| Zdroj: |
Journal of Microbiology, Immunology and Infection, Vol 57, Iss 4, Pp 554-563 (2024) |
| Druh dokumentu: |
article |
| ISSN: |
1684-1182 |
| DOI: |
10.1016/j.jmii.2024.02.004 |
| Popis: |
Background: Real-world vaccine effectiveness following the third dose of vaccination against SARS-CoV-2 remains less investigated among people with HIV (PWH). Methods: PWH receiving the third dose of BNT162b2 and mRNA-1273 (either 50- or 100-μg) were enrolled. Participants were followed for 180 days until the fourth dose of COVID-19 vaccination, SARS-CoV-2 infection, seroconversion of anti-nucleocapsid IgG, death, or loss to follow-up. Anti-spike IgG was determined every 1–3 months. Results: Of 1427 participants undergoing the third-dose COVID-19 vaccination, 632 (44.3%) received 100-μg mRNA-1273, 467 (32.8%) 50-μg mRNA-1273, and 328 (23.0%) BNT162b2 vaccine and the respective rate of SARS-CoV-2 infection or seroconversion of anti-nucleocapsid IgG was 246.1, 280.8 and 245.2 per 1000 person-months of follow-up (log-rank test, p = 0.28). Factors associated with achieving anti-S IgG titers >1047 BAU/mL included CD4 count 200 copies/mL (aOR, 0.27; 95% CI, 0.09–0.80), having achieved anti-spike IgG >141 BAU/mL within 3 months after primary vaccination (aOR, 3.69; 95% CI, 2.68–5.07), receiving BNT162b2 vaccine as the third dose (aOR, 0.20; 95% CI, 0.10–0.41; reference, 100-μg mRNA-1273), and having previously received two doses of mRNA vaccine in primary vaccination (aOR, 2.46; 95% CI, 1,75-3.45; reference, no exposure to mRNA vaccine). Conclusions: PWH receiving different types of the third dose of COVID-19 vaccine showed similar vaccine effectiveness against SARS-CoV-2 infection. An additional dose with 100-μg mRNA-1273 could generate a higher antibody response than with 50-μg mRNA-1273 and BNT162b2 vaccine. |
| Databáze: |
Directory of Open Access Journals |
| Externí odkaz: |
|
